DE9213914U1 - Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure - Google Patents
Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der ThioctsäureInfo
- Publication number
- DE9213914U1 DE9213914U1 DE9213914U DE9213914U DE9213914U1 DE 9213914 U1 DE9213914 U1 DE 9213914U1 DE 9213914 U DE9213914 U DE 9213914U DE 9213914 U DE9213914 U DE 9213914U DE 9213914 U1 DE9213914 U1 DE 9213914U1
- Authority
- DE
- Germany
- Prior art keywords
- thioctic acid
- solution
- water
- ampoule
- soluble salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 title claims description 33
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title claims description 32
- 235000019136 lipoic acid Nutrition 0.000 title claims description 32
- 229960002663 thioctic acid Drugs 0.000 title claims description 32
- 150000003839 salts Chemical class 0.000 title claims description 12
- 239000003708 ampul Substances 0.000 title claims description 8
- 239000003978 infusion fluid Substances 0.000 title claims description 6
- 229940126601 medicinal product Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- XZUAPPXGIFNDRA-UHFFFAOYSA-N ethane-1,2-diamine;hydrate Chemical compound O.NCCN XZUAPPXGIFNDRA-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001907 Mushroom Poisoning Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940030966 pyrrole Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE9213914U DE9213914U1 (de) | 1992-10-15 | 1992-10-15 | Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure |
| BE9300910A BE1007420A3 (fr) | 1992-10-15 | 1993-09-03 | Ampoules et solution de perfusion d'acides thioctique sous forme de sels solubles dans l'eau d'acide thioctique. |
| FR9311052A FR2696933B3 (fr) | 1992-10-15 | 1993-09-16 | Ampoules et solution de perfusion d'acide thioctique sous forme de sels solubles dans l'eau d'acide thioctique. |
| NL9301781A NL9301781A (nl) | 1992-10-15 | 1993-10-14 | Ampul en infuusoplossing van thioctzuur in de vorm van de in water oplosbare zouten van thioctzuur. |
| PT101388A PT101388B (pt) | 1992-10-15 | 1993-10-14 | Solucoes de infusao de acido tioctico sob a forma dos seus sais soluveis em agua e ampola para aplicacao parenteral |
| ES09302159A ES2063713B1 (es) | 1992-10-15 | 1993-10-14 | Ampolla y solucion para infusion de acido tioctico en forma de las sales solubles en agua del acido tioctico. |
| ITTO930761A IT1260996B (it) | 1992-10-15 | 1993-10-15 | Fiala a soluzione per infusione di acido tiottico in forma di sale idrosolubile dell'acido tiottico. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE9213914U DE9213914U1 (de) | 1992-10-15 | 1992-10-15 | Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE9213914U1 true DE9213914U1 (de) | 1992-12-03 |
Family
ID=6884846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE9213914U Expired - Lifetime DE9213914U1 (de) | 1992-10-15 | 1992-10-15 | Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE1007420A3 (pt) |
| DE (1) | DE9213914U1 (pt) |
| ES (1) | ES2063713B1 (pt) |
| FR (1) | FR2696933B3 (pt) |
| IT (1) | IT1260996B (pt) |
| NL (1) | NL9301781A (pt) |
| PT (1) | PT101388B (pt) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4433764A1 (de) * | 1994-09-22 | 1996-03-28 | Asta Medica Ag | Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit |
| ITMI20111975A1 (it) * | 2011-10-28 | 2013-04-29 | Labomar S R L | Composizioni comprendenti un sale di un acido organico. |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE29506604U1 (de) * | 1995-04-25 | 1995-06-14 | Asta Medica Ag, 01277 Dresden | Fertiginfusionsset |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0427246A2 (de) * | 1989-11-09 | 1991-05-15 | ASTA Medica Aktiengesellschaft | Arzneimittel, welche als Wirkstoff Schwefel enthaltende Carbonsäuren enthalten sowie deren Verwendung zur Bekämpfung von Retroviren |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1095991B (de) * | 1959-05-09 | 1960-12-29 | Chemiewerk Homburg Zweignieder | Verfahren zur Herstellung einer stabilen und injizierbaren 1,2-Dithia-cyclopentan-3-valeriansaeure enthaltenden Loesung |
| JPS3814940B1 (pt) * | 1961-03-04 | 1963-08-15 | ||
| JPS3922715B1 (pt) * | 1962-03-29 | 1964-10-13 | ||
| DE1668887B2 (de) * | 1968-03-15 | 1976-06-16 | Ca-salz der 1,2 -dithia-cyclopentan - 3- valerian saeure gleich (thioctsaeure) | |
| JPS4526516B1 (pt) * | 1968-07-08 | 1970-09-01 | ||
| JPS6066955A (ja) * | 1983-09-19 | 1985-04-17 | Kiyaraban:Kk | ドレッシングの製造方法 |
| IT1213141B (it) * | 1984-02-17 | 1989-12-14 | Dobrivoje Tomic | Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche. |
| DE3512911A1 (de) * | 1985-04-11 | 1986-10-16 | Degussa Ag, 6000 Frankfurt | Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure) |
| ATE70974T1 (de) * | 1987-12-04 | 1992-01-15 | Asta Pharma Ag | Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren. |
| JPH03169813A (ja) * | 1989-11-09 | 1991-07-23 | Asta Pharma Ag | 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法 |
-
1992
- 1992-10-15 DE DE9213914U patent/DE9213914U1/de not_active Expired - Lifetime
-
1993
- 1993-09-03 BE BE9300910A patent/BE1007420A3/fr not_active IP Right Cessation
- 1993-09-16 FR FR9311052A patent/FR2696933B3/fr not_active Expired - Lifetime
- 1993-10-14 ES ES09302159A patent/ES2063713B1/es not_active Expired - Fee Related
- 1993-10-14 NL NL9301781A patent/NL9301781A/nl active Search and Examination
- 1993-10-14 PT PT101388A patent/PT101388B/pt not_active IP Right Cessation
- 1993-10-15 IT ITTO930761A patent/IT1260996B/it active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0427246A2 (de) * | 1989-11-09 | 1991-05-15 | ASTA Medica Aktiengesellschaft | Arzneimittel, welche als Wirkstoff Schwefel enthaltende Carbonsäuren enthalten sowie deren Verwendung zur Bekämpfung von Retroviren |
Non-Patent Citations (1)
| Title |
|---|
| Rote Liste 1991 Nr.66 015 Amp.10 ml Herausgeber: Bundesverband der Pharmazeutischen Industrie e.V., Frankfurt a.M. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4433764A1 (de) * | 1994-09-22 | 1996-03-28 | Asta Medica Ag | Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit |
| ITMI20111975A1 (it) * | 2011-10-28 | 2013-04-29 | Labomar S R L | Composizioni comprendenti un sale di un acido organico. |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1260996B (it) | 1996-04-29 |
| ITTO930761A1 (it) | 1995-04-15 |
| ITTO930761A0 (it) | 1993-10-15 |
| BE1007420A3 (fr) | 1995-06-13 |
| NL9301781A (nl) | 1994-05-02 |
| PT101388A (pt) | 1994-09-30 |
| ES2063713B1 (es) | 1995-07-16 |
| FR2696933B3 (fr) | 1994-09-23 |
| PT101388B (pt) | 1999-09-30 |
| FR2696933A3 (fr) | 1994-04-22 |
| ES2063713A1 (es) | 1995-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
| DE3528979A1 (de) | Arzneimittelfreigabesystem | |
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| EP0318891B1 (de) | Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren | |
| AT397462B (de) | Wässerige piroxicamlösungen | |
| EP0254902B1 (de) | Lösungen von Oxazaphosphorinen mit verbesserter Stabilität und Verfahren zu deren Herstellung | |
| DE4220851A1 (de) | Verwendung von schwefel enthaltenden carbonsaeuren zur bekaempfung von pathophysiologisch bedingten erregungsstoerungen und von hierdurch bedingten erkrankungen sowie von allergischen erkrankungen sowie die herstellung entsprechender arzneimittel | |
| DE3623620A1 (de) | Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung | |
| DE3536560A1 (de) | Augentropfen enthaltend bromokryptin | |
| DE69300017T2 (de) | Wässrige pharmazeutische Zubereitung von Natriumcromoglykat. | |
| DE69920468T2 (de) | Stabilisierte carvedilol-injektionslösung | |
| DE9213914U1 (de) | Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure | |
| EP1073469B1 (de) | Stabile mitoxantron-lösungen | |
| DE69937574T2 (de) | Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen | |
| DE2743704C2 (de) | L- oder DL-Phenylglycine enthaltende Arzneimittel | |
| DE2335729A1 (de) | Vincanolsalze, verfahren zu deren herstellung und diese verbindungen als wirkstoffe enthaltende pharmazeutische zubereitungen | |
| DE3840076A1 (de) | Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren | |
| EP0591710A1 (de) | Mesna-Injektionslösungen | |
| DE68905995T2 (de) | Parenteral anzuwendende 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1h-imidazol-4-yl)-methyl)-piperazin enthaltende zubereitungen. | |
| CH654744A5 (de) | Waessrige pharmazeutische formulierung auf basis eines vincaalkaloids. | |
| DE2546474A1 (de) | Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung | |
| DE69426295T2 (de) | Organkonservierungsmittel | |
| EP0005732A1 (de) | Verwendung von 2-Amino-oxazolo- oder 2-Amino-thiazolo-[5,4-d]azepinen sowie deren Säureadditionssalzen zur Herstellung eines Arzneimittels für die Verwendung bei der Bekämpfung von Angina Pectoris | |
| DE2358123A1 (de) | Infusionsmaterial und verfahren zu seiner herstellung | |
| DE2844534C2 (pt) |